Baird upgrades Novanta stock rating on growth outlook

Baird upgraded Novanta to Outperform and lowered its price target to $144 from $150 while citing attractive exposure to robotic surgery, warehouse/humanoid robotics and additive manufacturing and noting a potential acquisition as a positive catalyst. Novanta reported Q4 2025 EPS of $0.91 (met consensus) and revenue of $258.3M (slightly above forecasts); the stock trades at $113.15, down 4.9% YTD and 3.6% over the past month, trading at a P/E of 77 with an InvestingPro fair value of $134.86. The company joined NVIDIA’s Halos AI Systems Inspection Lab to validate interoperability of its motion control and sensing tech, a strategic move expected to ease OEM integration and speed time-to-market.

Analysis

Novanta sits at an inflection where software-driven interoperability (via the NVIDIA validation pathway) can convert a previously bespoke integration cycle into a repeatable, certified stack — that should raise gross margin potential and shorten sales cycles for new robotics platforms within 12–24 months. The market is pricing growth into a 77x P/E today, so absent a visible near-term earnings uplift or a transaction, multiple compression is the primary downside; conversely, a bolt-on acquisition meeting management’s criteria or a clear conversion of backlog-to-revenue could re-rate the stock by +20–30% within 6–12 months. Second-order winners include high-precision sensor and motion-control suppliers that feed Novanta’s modules (they could see volume leverage as OEMs standardize on validated stacks), while small system integrators that monetize bespoke integration work risk margin erosion as certification replaces custom engineering. Tail risks to the bullish case are macro industrial capex softness and slower-than-expected adoption in surgical robotics reimbursement cycles; either could push the revenue inflection beyond the 12–24 month window and expose the stock’s high multiple to rapid downside.

Key Decisions for Investors

• Long NOVT stock (size 1–2% NAV) with a 6–12 month horizon: buy into weakness toward $100–105, target $144 (Baird PT) for ~27% upside, hard stop-loss at ~20% below entry (~$82–90). Rationale: capture both inflection from backlog conversion and potential M&A re-rate while keeping position-sized for multiple-compression risk.
• Defined-risk options trade: buy NOVT Jan 2027 110/150 call spread (or equivalent LEAP bull-call spread) to express the acquisition/inflection thesis with limited capital at risk; expect 2:1+ skew if a catalyst (deal or strong bookings) materializes within 6–12 months.
• Pair trade for sector rotation (6–12 months): long NOVT / short ROK (Rockwell Automation) equal-dollar to express a shift toward modular, certified robotics stacks and away from legacy PLC-centric automation. This reduces market beta and isolates share-shift risk; unwind if Rockwell reports accelerating robotics integration wins.
• Risk-management: if initiating a position, buy 6–9 month protective puts (or scale into covered-call writing after a 15–20% move up). Reassess if backlog conversion misses two consecutive quarters or if NVIDIA partnership shows no quantifiable pipeline benefit by Q4 next fiscal year.